Aims: Glycogen synthase kinase 3β (GSK-3β) is activated following hypoxic-ischemic (HI) brain injury. TDZD-8 is a specific GSK-3β inhibitor. Currently, the impact of inhibiting GSK-3β in neonatal HI injury is unknown. We aimed to investigate the effect of TDZD-8 following neonatal HI brain injury.
| INTRODUCTION
Glycogen synthase kinase 3β (GSK-3β) is a constitutively active serine/ threonine kinase that is expressed in all tissues. In the central nervous system, GSK-3β is highly expressed in brain regions including the cerebral cortex, hippocampus, and cerebellum. [1] [2] [3] [4] Under physiological conditions, GSK-3β plays important roles in neuronal polarization 5, 6 , neurogenesis 7, 8 and axonal growth. 9, 10 Under pathological conditions, overactivation of GSK-3β is involved in pro-apoptosis of neurons 11 and dysregulation of this kinase has a devastating effect on neurodevelopment. 12 GSK-3β has been reported to be involved in stroke pathology.
In transient middle cerebral artery occlusion models, GSK-3β expression levels increased following 90 minutes of ischemia and 4 hours of reperfusion. 13 Selective inhibition of the GSK-3β isoform using pharmacological tools (ie, TDZD-8, Chir025) resulted in reduction of cerebral infarction, oxidative stress, and apoptosis, suggesting the
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GSK-3β isoform as a drug target for neuroprotection. 14, 15 Inhibition of GSK-3β is thought to mediate neuroprotection against stroke through multiple mechanisms, including regulation by PI3K/Akt prosurvival signaling, interaction with MAPK, and nuclear factor-kappa B signaling pathways. [14] [15] [16] [17] [18] Neonatal hypoxic-ischemic (HI) brain injury and its related disease hypoxic-ischemic encephalopathy (HIE) are global brain injuries that impact three to five per 1000 live births. Neonatal HI results in a mortality rate of 15%-20%. 19 In survivors, approximately 25% suffer from lifelong neurological deficits including mental retardation and epilepsy, making neonatal HI a leading cause of neurological impairment in children. 19 Hypothermia has now emerged as an effective therapy of neonatal HI. 20, 21 Given the incomplete protection from HI afforded by hypothermia, other neuroprotective strategies are currently in clinical trials including prophylactic barbiturates, 22 erythropoietin, 23 and allopurinol. 24 Recent studies showed that inhibition of GSK-3β by SB216763 and granulocyte-colony stimulating factor elicited neuroprotection in neonatal rodents. 18, 25 We have recently shown that HIinduced brain injury in the neonatal mouse models [26] [27] [28] is mediated via caspase-3-dependent cell death pathway. Inhibiting caspase-3 resulted in neuroprotection in several neonatal hypoxic-ischemic injury models. [29] [30] [31] The Akt/GSK-3β pathway is a major signaling that is known to tightly regulate caspase-3 activation. 11, [26] [27] [28] Thus, we hypothesized that inhibition of GSK-3β would ameliorate neonatal hypoxic-ischemic brain injury.
has been shown to have neuroprotective, antiinflammatory, and antioxidative effects. [32] [33] [34] Prophylactic administration of TDZD-8 in adult rats increased phosphorylation of GSK-3β (Ser9) site and reduced brain damage following cerebral ischemia/reperfusion injury via inhibition of the apoptotic pathway and reactive oxygen species (ROS) production. 15 GSK-3β is involved in neuronal development processes, but it is unknown whether GSK-3β inhibitor TDZD-8 may play a protective role in hypoxic stress in immature animals. In this study, we report that TDZD-8 prevented the reduction of p-GSK-3β and brain injury in the HI model, suggesting that phosphorylation of GSK-3β at the Ser9 site plays a crucial role in neuroprotection in the neonatal stage.
| MATERIAL AND METHODS

| Animals
All protocols were carried out in compliance with the Canadian Council on Animal Care (CCAC guidelines), and all animal experimental procedures were approved by the local Animal Care and Use Program
Committee (Office of Research Ethics at the University of Toronto).
Timed-pregnant CD1 mice were purchased from Charles River Laboratories (Sherbrooke, QC, Canada) and housed at an ambient temperature of 23±1°C and a 12-hour light/dark cycle with food and water fed ad libitum. Pups were timed as postnatal day 0, P0, on their day of birth, and P7 pups of either sex were used for experiments. A total of 104 pups were used for this study. Body weight was used as a general indicator of health, and any pups below 4 grams at P7 were not used.
| Reagents and drugs
Cresyl violet, 2,3, 5-triphenyl-2H-tetrazolium chloride (T8877, TTC) and Dimethyl sulfoxide (D2650, DMSO) were purchased from SigmaAldrich (St. Louis, MO, USA). TDZD-8 was supplied by Centro de
Investigaciones Biologicas-CSIC (CIB-CSIC; Madrid, Spain). 35 
| Drug administration
Pups were randomly selected to receive TDZD-8 or vehicle treatment. TDZD-8 (5 mg/kg) or vehicle control containing 5% DMSO and 5% Tween-80 (P-8074) in 0.9% saline 36, 37 was administered to the pups 20 minutes prior to ischemia induction. These compounds were administered intraperitoneally (i.p.) with a volume to body weight injection ratio of 20 μL/g. Sham-operated animals were injected with vehicle.
| Hypoxic-ischemic brain injury model
Hypoxic-ischemic brain injury was induced in P7 pups as previously described. [26] [27] [28] Briefly, anesthesia was induced and maintained with 3% and 1.5% inhaled isoflurane in oxygen, respectively. The right common carotid artery was exposed and ligated using a bipolar electrocoagulation device (Summit Hill Laboratories, Tinton Falls, NJ, USA). Body temperature was maintained during the surgery with a heat blanket. Following the surgery, pups were placed in a recovery cage under a heat lamp for 5 minutes until they regained consciousness and were returned to their home cage for 90 minutes. After the recovery period, pups were placed in an airtight hypoxic chamber (Biospherix, NY, USA) fed with humidified 7.5% oxygen in mixture with 92.5% nitrogen gas for 60 minutes. The chamber temperature was maintained at 37°C using a homoeothermic blanket control unit (MA, USA). After hypoxia, the pups were recovered under a heat lamp for 5 minutes and were returned to their home cage. Sham animals were anesthetized, and their common carotid artery was exposed and separated but no ligation or hypoxia took place.
| Whole-brain imaging, histological assessments, and infarct volume measurement
TTC staining/Infarct Volume Measurement [26] [27] [28] : Twenty-four hours after HI injury, whole brains were removed from the pups and sectioned coronally into ~1-mm slices used for TTC staining. Slices were stained with 1% TTC and placed in a dark incubator maintained at 37°C for 20 minutes.
Whole-Brain Imaging/Nissl Staining: Seven days after HI injury, whole brains were removed, fixed, imaged, and sectioned coronally into ~100-μm slices used for Nissl staining (1% cresyl violet).
The corrected infarct volumes for TTC and whole-brain imaging were calculated as follows: Corrected infarct volume (%)=(contralateral hemisphere volume−ipsilateral hemisphere+in-farct volume)/contralateral hemisphere volume×100%. 28, 38, 39 The hemispheric and infarct volumes for the whole brains were traced and then quantified using the ImageJ software (National institute of Health, Bethesda, MD, USA). For TTC quantification, the hemispheric/infarct areas of each brain slice was traced and quantified using the same software.
| Neurobehavioral assessments
| Geotaxis reflex
This reflex assessed the animal's balance and proprioception. [26] [27] [28] 40 Neonatal mice were positioned on a 45° inclined wooden board such that the animal's head was pointed downward, and the time latency for them to rotate 90° (either left or right) was determined.
The maximum time allocated for each trial of behavioral observation was 20 seconds, and any trial past the maximum time was scored as 20 seconds. 
| Cliff avoidance reflex
This test was used to assess the animal's capacities in both locomotion and external sensation. [26] [27] [28] 40 Mouse pups were first placed on the wooden board such that their front paws were in an overhanging position relative to the board. The amount of time taken for the mouse to successfully evade the cliff by turning the body 90°
(either left or right) was determined. A maximum time of 20 seconds was used in a similar manner as compared to the geotaxis reflex test. 40 
| Western blot
Western blot procedures were performed as previously described. [26] [27] [28] Twenty-four hours after HI, the ipsilateral hemispheres were removed and frozen in dry ice. To study the developmental expression of GSK-3β, protein was extracted from cortex. The brain samples were homogenized in RIPA buffer with proteinase and phosphatase inhibitors. Samples of the mouse brain (30 μg)
were separated on a 10% SDS-PAGE gel that was transferred to a nitrocellulose membrane (350 mA, 90 minutes). Blots were blocked with 5% nonfat dry milk in Tris-buffered saline, and incubated with primary and secondary antibodies at 4°C overnight and room temperature, respectively (anticleaved caspase-3, #9664S, 1:1000;
antiphospho-Akt (#9271S, Ser473, 1:1000); anti-Akt (#9272S, 1:1000); antiphospho-GSK-3β (#9323S, Ser9, 1:1000); anti-GSK-3β (#9832S, 1:1000); anti-GAPDH (#2118S, 1:10,000). All the primary antibodies were from Cell Signaling Technology (Danvers, MA, USA). Protein signals of interest were visualized using enhanced chemiluminescent reagents (PerkinElmer, Boston, MA, USA) and analyzed by exposure to film (HyBlot CL, Metuchen, NJ, USA).
| Immunohistochemistry and confocal imaging
Brain samples were collected 7 days after HI at P14 and fixed in 4% paraformaldehyde/30% sucrose solution at 4°C overnight. Brains were coronally sectioned into ~50-μm slices using a vibratome (Tissue Sectioning System Microtome Vibratome, HuiYou, China) and immunohistochemically stained as previously described. 28 In brief, samples were probed with mouse antineuronal nuclei (NeuN)
antibody ( 
| In situ hybridization and 3D imaging
In situ hybridization (ISH) data were collected from Allen Brain AtlasDeveloping Mouse Brain website (http://developingmouse.brainmap.org/). Data were taken from C57BL/6J mice at developmental time points: E18.5, P4, P14, and P28; 3D imaging was performed using the Allen Developing Mouse Brain Atlas-Brain Explorer 2 software.
41
Gene expression data measured as intensity level were plotted as a series of grid points for each brain slices superimposed on each other.
| Data analysis
All statistical analyses were performed using statistical software SigmaPlot (Systat Software, San Jose, CA, USA). Data are presented as mean±SEM. Student's t test was used to determine the statistical difference between two groups. Multiple-group statistical analysis was performed using one-way ANOVA test followed by Fisher LSD Method for multiple pairwise comparisons. A P-value of <.05 (P<.05) was considered statistically significant. All experiments were conducted in a blinded manner; experimenters did not know the treatment conditions. All experiments were repeated at least three times.
| RESULTS
| TDZD-8 pretreatment attenuates infarct volume following hypoxic-ischemic brain injury
First, we investigated whether TDZD-8 can reduce brain damage using a hypoxic-ischemic brain injury model in neonatal mice. Subsequent ( Figure 2B ). These results demonstrated that TDZD-8 pretreatment reduces brain damage induced by HI 7 days after injury in neonatal mice.
| TDZD-8 improves neurobehavioral outcome following hypoxic-ischemic brain injury
We next addressed whether the reduction in brain damage observed in the TDZD-8-treated HI group led to improved sensorimotor function in this model. Seven days after HI, we assessed the neurobehavioral function of mice using the cliff avoidance test and geotaxis reflex.
| Cliff avoidance test
The vehicle control group (7 days: 6.14±1.63 seconds) displayed a significantly longer latency to complete the test in comparison with the sham group (7 days: 2.03±0.15 seconds). TDZD-8 pretreatment These results indicated that TDZD-8 improves the locomotion and reduces maladaptive behavior response of the mice following HI. 
| Geotaxis reflex test
| Developmental expression of GSK-3β and Akt
To understand the role of GSK-3β in neuronal death following hypoxicischemic injury in neonatal mice, we studied the physiological gene expression of the kinase during development. ISH data obtained from Allen Brain Atlas: Developing Mouse Brain 41 revealed that GSK-3β gene expression is localized in the mouse cortex and hippocampus during early and late stages of brain development measured at E18.5, P4, P14, and P28 ( Figure 4A ). Importantly, the cortex and hippocampus are brain areas most vulnerable to hypoxic-ischemic injury in rodents. 42 While gene expression of GSK-3β was similar in E18.5 and P14 but lower at P28 times points, highest intensity levels were seen at P4 ( Figure 4A ).
Next, we studied the protein expression levels of total GSK-3β at E17, P7, and P14 time points ( Figure 4B-E) . The level of phosphorylated GSK-3β (p-GSK-3β), the inactive form of the protein, was labeled with an antibody binding to the Serine 9. As shown in Figure 4C , the p-GSK-3β level was significantly higher at E17 (1.41±0.10) and P7 (1.65±0.40) than at P14 (0.64±0.23). Also, we found that total GSK-3β protein levels was highest at P7 (1.36±0.14) compared to E17 (1.07±0.02) and P14 (1.02±0.03) time points ( Figure 4D) ; there was no significant difference between E17 and P14. The p-GSK-3β
to t-GSK-3β ratio was compatible between E17 (1.32±0.07) and P7 protein levels of GSK-3β and Akt at E17, P7, and P14. Analysis of band intensity showing the ratio of (C) p-GSK3β to GAPDH, (D) t-GSK3β to GAPDH, and (E) p-GSK3β to t-GSK3β. Analysis of band intensity showing the ratio of (F) p-Akt to GAPDH, (G) t-Akt to GAPDH, and (H) p-Akt to t-Akt. (*P<.05 vs sham group or TDZD-8 treatment group; One-way ANOVA followed by Fisher LSD Method). E17 group, n=5; P7 group, n=4; P14 group, n=5
to postnatal day 7 but increased 14 days following birth. We also measured the changes in Akt expression levels at these time points ( Figure 4B, F-H) . The p-Akt to t-Akt ratio was significantly higher at age P7 (0.94±0.07) compared to E17 (0.61±0.09) and P14 (0.51±0.13) (P<.05; n=5). The p-Akt to t-Akt ratios between E17 and P14 were compatible ( Figure 4H ).
| TDZD-8 pretreatment increases Serine-9-phosphorylated GSK-3β (p-GSK-3β) and phosphorylated Akt (p-Akt) levels after hypoxicischemic brain injury
Next, we asked whether TDZD-8 treatment would affect the level of p-GSK-3β after HI injury. We found that the ratio of p-GSK-3β/ GSK-3β was significantly increased in the TDZD-8-treated HI group (0.69±0.02) compared to the vehicle-treated HI group (0.36±0.13, Figure 5A , B). Our results showed that p-Akt/t-Akt expression ratio was significantly increased after pretreatment with TDZD-8 (0.85±0.11) compared to the vehicle-treated group (0.47±0.12, P<.05, Figure 5C ). This finding supports the hypothesis that TDZD-8 promotes prosurvival signaling by directly or indirectly activating p-Akt following the HI injury.
P<.05,
| TDZD-8 pretreatment suppresses apoptotic signaling after hypoxic-ischemic brain injury
We have previously shown that mitochondrial-mediated apoptosis is one of the main mechanisms for cell death following neonatal hypoxicischemic brain injury. hemispheres of the vehicle-treated group(68.0±7.13); the sham group had the lowest levels of cleaved caspase-3 ( Figure 6A , B).
| TDZD-8 reduces GFAP-positive cells and maintains NeuN-positive cells following hypoxicischemic brain injury
To investigate the nonneuronal cell involvement in hypoxia-ischemia, 
| DISCUSSION
In this study, we showed that the levels of GSK-3β mRNA and total protein were significantly higher in P7 pups than at E17 and 14 days and the ratio of p-GSK-3β/t-GSK-3β was reduced significantly at P14 compared to E17 and P7. We also demonstrated that treatment with TDZD-8 (i) reduced cerebral infarct volume following the HI injury;
(ii) improved neurobehavioral recovery outcomes after the HI injury and increased the phosphorylation of GSK-3β; (iii) reduced cleaved caspase-3 protein levels and increased the expression of prosurvival It has been show that TDZD-8 reduced brain injury following cerebral ischemia in adult mice 15 ; however, its effect in neonatal mice remains unclear. We found that pretreatment with TDZD-8 reduced the brain damage and improved neurobehavioural test scores of the mice following HI. During development, the p-Akt/t-Akt and p-GSK-3β/t-GSK-3β protein ratios are high at the age of P7, which corresponds to a high Akt and low GSK-3β activity. Following HI, the p-Akt/t-Akt and p-GSK-3β/t-GSK-3β levels decreased significantly in our vehicle control group, which indicates that these molecules play an important role in the pathology of HI. The reduction of p-Akt and p-GSK-3β levels was found to cause an increase in cleaved caspase-3 levels indicating the involvement of apoptotic signaling. 44, 45 Our results verified that TDZD-8 reduced brain injury following HI injury in neonatal mice and support that pretreatment with TDZD-8 elicited neuroprotection through restoring p-Akt/t-Akt and p-GSK-3β/t-GSK-3β levels which led to suppression of cleaved caspase-3-mediated apoptotic signaling.
Caspase-3 has been a prominent marker of apoptosis and was shown to be upregulated following neonatal HI, while inhibition of caspase-3 resulted in neuroprotection against hypoxic-ischemia. 30 Previous studies have shown that phosphorylation of Akt (p-Akt) inhibited GSK-3β leading to the suppression of caspase-3-mediated apoptotic signaling; this suggests a possible link between GSK-3β regulation and cell death in our model. 11, 46, 47 Specifically, upstream activation of GSK-3β after hypoxic-ischemic injury leads to decreased Bcl-2 expression, which in turn activates caspase-3. 48 In this study, we found that cleaved caspase-3 protein expression levels were very low in the treatment group compared with the number of cleaved caspase-3 containing cells in our immunohistochemistry data ( Figure 6A , B). The differences seen in cleaved caspase-3 levels could be attributed to the differences in the age of the brain samples, timing of caspase-3 expression, and the pharmacological half-life of TDZD-8. Specifically, the brain samples used for Western blot analysis were collected 24 hours following HI whereas the brain samples used for immunohistochemistry were collected 7 days following HI. While caspase-3 levels are present during both the early and late phases of ischemia, caspase-3 levels are predominately expressed from 72 hours to 7 days after ischemia injury. 49 Moreover, TDZD-8 has a half-life of 120 minutes 50 ; thus, it is likely that TDZD-8 exerted a greater effect early after the onset of injury (24 hours) compared to a later stage (7 days). This supports the idea that during early stages of ischemia, TDZD-8-mediated phosphorylation of GSK-3β leads to decrease of caspase-3 expression seen in our Western blot. However, during later stages of ischemia, it is possible that p-GSK-3β is dephosphorylated as the effect of TDZD-8 becomes diminished resulting in a relative increase in caspase-3 levels seen in the immunohistochemistry data.
Additionally, sex differences exist in caspase-3 activation in both adult and neonatal mice after stroke. Female mice usually display a stronger activation of caspase-3, 51 while, in the present study, we used both male and female pups. The differences between male and female animals in their response to TDZD-8 are still needed to be illustrated in the future.
Hypoxic-ischemic injury can compromise the normal function of astrocytes leading to detrimental secondary effects on neuronal cells.
Specifically, pathologically activated astrocytes (reactive astrocytes)
have been shown to mediate the inflammatory response [52] [53] [54] and express caspase-3 apoptotic markers 55 leading to secondary cerebral damage. In this study, we used GFAP, an indicator for reactive astrogliosis, as a marker for neurological damage following neonatal HI injury.
GFAP is a sensitive marker for reactive astrocytes. 56, 57 In Figure 7A , it can be seen that the vehicle group had severe reactive astrogliosis with overlapping and hypertrophic astrocytes. In the TDZD-8-treated group, reactive astrocytes were fewer in number and shared fewer overlapping regions. Further studies need to address the link between GSK-3β and reactive astrogliosis following HI injury.
| CONCLUSION
We showed that pretreatment with specific GSK-3β inhibitor TDZD-8 was neuroprotective against neonatal hypoxic-ischemic brain injury.
The primary mechanism of action is suggested to involve the reduction of HI-induced apoptosis and reactive astrogliosis and upregulation of prosurvival signaling. TDZD-8 pretreatment reduced brain damage and improved behavioral recovery, thus making it a potential preventative drug in treatment of neonatal hypoxic-ischemic brain injury. It is important to note that our present work mainly focused on the preventive effect of TDZD-8 against hypoxic-ischemic insult. While it is clinically relevant in specific situations, future studies are needed to investigate the therapeutic effects of TDZD-8 after the hypoxic-ischemic injury, and the potential therapeutic window for administering TDZD-8 after an injury. Given the widespread use of therapeutic hypothermia in the clinical care of neonates with HI, the impact of TDZD-8 on brain injury when administered with hypothermia also needs to be determined.
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